iRhythm Holdings (ITRC) receives negative mention from Spruce Point Capital

A negative mention from Spruce Point places iRhythm in the well-worn activist short-seller sequence: an initial critical note or social media flag, a sharp gap lower on the open, then a fork between a full dossier with a published price target and a one-off comment that fades. Spruce Point's established pattern is forensic accounting and governance critiques aimed at mid-caps, with the fuller reports historically producing the more durable moves and teaser mentions often retracing part of the initial drop within sessions. The tells that matter are whether a detailed report follows, whether management issues a point-by-point rebuttal or stays silent, and whether borrow costs and options skew confirm sustained positioning rather than a headline trade. For a diagnostics name like iRhythm, past short campaigns against medtech peers have centred on reimbursement durability, revenue recognition and channel stuffing, so those are the lines of attack to anticipate. Subsequent analyst responses and any auditor or regulatory angle are the usual second-leg catalysts in episodes of this kind.